Otsuka Pakistan Limited, a prominent subsidiary of Japan-based Otsuka Pharmaceutical Company Limited, has announced a temporary suspension of its production and manufacturing operations at its Hub plant in Balochistan. The company made this disclosure in a formal notice to the Pakistan Stock Exchange on Wednesday January 1, confirming the upcoming shutdown for scheduled annual maintenance.

The suspension is set to begin on January 6, 2025, and will extend until January 19, 2025, with both dates included in the closure period. The company clarified that this temporary halt in operations is part of routine maintenance activities, which are crucial to ensuring the ongoing efficiency and safety of the plant. By adhering to the necessary maintenance procedures, Otsuka Pakistan aims to maintain the high standards of operation that align with both international safety regulations and its own quality benchmarks.

In its notice, the company emphasized that the maintenance work is necessary to guarantee that all systems and processes at the Hub plant continue to operate smoothly. Routine maintenance, according to Otsuka Pakistan, is essential for minimizing disruptions and ensuring that the production facilities are in optimal condition. The company has also assured its stakeholders that every possible measure is being taken to mitigate any potential adverse effects on operations or commitments during this period.

Despite the temporary suspension of activities, Otsuka Pakistan reassured the public and its business partners that this maintenance work will not significantly disrupt its supply chain. The company has reportedly taken proactive steps to ensure that there is no interruption to the availability of its products during the shutdown.

Otsuka Pakistan Limited, which was incorporated in Pakistan as a public limited company in 1988, plays a key role in the manufacturing, marketing, and distribution of intravenous infusions. In addition to its core activities in pharmaceuticals, the company also deals in medical equipment and nutritional foods. The Hub plant, located in the southwestern province of Balochistan, is one of the company’s main production facilities, supporting its broad portfolio of healthcare products.

As a subsidiary of Otsuka Pharmaceutical Company Limited, a globally recognized leader in the pharmaceutical industry, Otsuka Pakistan benefits from its parent company’s strong research and development capabilities. This connection allows Otsuka Pakistan to maintain a robust presence in the market and to contribute to the improvement of healthcare in Pakistan through the provision of high-quality medicines and health solutions.

The company remains optimistic that the maintenance work will be completed on schedule and that production will resume without any major complications.